JP2023500045A5 - - Google Patents

Info

Publication number
JP2023500045A5
JP2023500045A5 JP2022522274A JP2022522274A JP2023500045A5 JP 2023500045 A5 JP2023500045 A5 JP 2023500045A5 JP 2022522274 A JP2022522274 A JP 2022522274A JP 2022522274 A JP2022522274 A JP 2022522274A JP 2023500045 A5 JP2023500045 A5 JP 2023500045A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
compound
administered
composition according
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022522274A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023500045A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/055633 external-priority patent/WO2021076666A1/en
Publication of JP2023500045A publication Critical patent/JP2023500045A/ja
Publication of JP2023500045A5 publication Critical patent/JP2023500045A5/ja
Pending legal-status Critical Current

Links

JP2022522274A 2019-10-14 2020-10-14 Ｓｔｉｎｇアゴニストを用いたがんを処置する方法 Pending JP2023500045A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962914881P 2019-10-14 2019-10-14
US62/914,881 2019-10-14
PCT/US2020/055633 WO2021076666A1 (en) 2019-10-14 2020-10-14 Methods of treating cancer with a sting agonist

Publications (2)

Publication Number Publication Date
JP2023500045A JP2023500045A (ja) 2023-01-04
JP2023500045A5 true JP2023500045A5 (cg-RX-API-DMAC7.html) 2023-10-19

Family

ID=73060121

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022522274A Pending JP2023500045A (ja) 2019-10-14 2020-10-14 Ｓｔｉｎｇアゴニストを用いたがんを処置する方法

Country Status (7)

Country Link
US (1) US20230270773A1 (cg-RX-API-DMAC7.html)
EP (1) EP4045059A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023500045A (cg-RX-API-DMAC7.html)
CN (1) CN114929241A (cg-RX-API-DMAC7.html)
AU (1) AU2020366354A1 (cg-RX-API-DMAC7.html)
CA (1) CA3157849A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021076666A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022014110A (es) * 2020-05-15 2023-01-30 Immunesensor Therapeutics Inc Tratamientos combinados de agonistas de sting con inhibidores de puntos de control inmunitario.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ746112A (en) * 2016-03-18 2023-01-27 Immune Sensor Llc Cyclic di-nucleotide compounds and methods of use
AU2017378782A1 (en) * 2016-12-20 2019-07-04 Merck Sharp & Dohme Corp. Combinations of PD-1 antagonists and cyclic dinucleotide sting agonists for cancer treatment
WO2018118665A1 (en) * 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Cyclic dinucleotide sting agonists for cancer treatment

Similar Documents

Publication Publication Date Title
AU2024200203B2 (en) Methods for the treatment of recurrent glioblastoma (RGBM)
AU2013402794B2 (en) Cancer treatment with combination of plinabulin and taxane
JP2019065028A5 (cg-RX-API-DMAC7.html)
JP6114257B2 (ja) アフリバーセプト、フォリン酸、５−フルオロウラシル（５−ｆｕ）及びイリノセタン（フォルフィリ）を含む組成物
JP2020033360A5 (cg-RX-API-DMAC7.html)
JP2007515469A5 (cg-RX-API-DMAC7.html)
Kohn et al. Phase II trial of intermittent high-dose recombinant interferon alfa-2a in mycosis fungoides and the Sézary syndrome.
JP2011511072A5 (cg-RX-API-DMAC7.html)
JP2020516646A5 (cg-RX-API-DMAC7.html)
FI3463345T3 (fi) Farmaseuttisia yhdistelmiä
JP2017510579A5 (cg-RX-API-DMAC7.html)
JP2017529382A5 (cg-RX-API-DMAC7.html)
IL320452A (en) Combination therapy for prostate cancer
JP2002544231A5 (cg-RX-API-DMAC7.html)
JP2024524461A5 (cg-RX-API-DMAC7.html)
Librodo et al. Chronotherapeutic drug delivery
EP1201247B1 (en) Treatment of metastatic renal cell carcinoma
JP2023500045A5 (cg-RX-API-DMAC7.html)
JP2022540759A5 (cg-RX-API-DMAC7.html)
JP2021511344A5 (cg-RX-API-DMAC7.html)
CA2483826A1 (en) Epothilone derivative for the treatment of hepatoma and other cancer diseases
JP2010504307A5 (cg-RX-API-DMAC7.html)
JP2023011549A5 (cg-RX-API-DMAC7.html)
JP2024540044A5 (cg-RX-API-DMAC7.html)
Solomon et al. Rituximab is more effective than tacrolimus in steroid-dependent nephrotic syndrome